Europe Plant-based Vaccines Market

Market Introduction

The Europe Plant-based vaccines market includes the consolidated markets for Germany, France, the United Kingdom, and Rest of Europe. Europe is the second largest market in the forecast period owing to factors such as rising geriatric population, increasing prevalence of chronic viral diseases, and high demand for the development of new antigen in the region. In addition, growing funding for research & development activities is likely to add more opportunities in coming years, in the region.

Reliable and timely COVID-19 testing is an integral part of the monitoring, prevention, touch recording, and control of infections, and clinical management of COVID-19. The European Center for Disease Prevention and Control (ECDC) has proposed an analytical testing strategy for the EU with concrete guidelines on the level of dissemination of viruses in the population, considering the available public health tools and testing ability. A survey undertaken by the European Commission Health Protection Committee in September 2020 investigated the activities of Member States in the use of rapid antigen tests. Fifteen EU member states responded to the survey, out of them five states are using rapid antigen tests on certain aspects of the response to the COVID-19 pandemic. Nine of the fifteen countries are currently conducting clinical validation trials or pilots to evaluate the clinical/diagnostic efficiency and future use of rapid antigen tests, and 2 member states are not considering the use of rapid antigen tests. According to the report, some countries use the tests as part of their research policy for early detection of infection, contact tracking and/or rapid isolation, and quarantine of identified cases and their contacts. Other countries use rapid antigen tests explicitly to ensure laboratory testing in remote areas where the RT-PCR gold standard is not available or timely enough.                    

Market Overview and Dynamics

The plant-based vaccines market in Europe is expected to grow from US$ 306.40 million in 2021 to US$ 705.15 million by 2028; it is estimated to grow at a CAGR of 12.6% from 2021 to 2028. influenza is a highly contagious respiratory ailment caused by influenza viruses. Influenza viruses are constantly changing genetically, highly impacting induced immunity and vaccine formulation. According to the World Health Organization (WHO), when infected individual coughs or sneezes, droplets containing viruses (infectious droplets) are disseminated into the air and can travel up to one-meter, infecting people in close proximity who breathe these droplets in. Pregnant women, pediatricians, geriatricians, patients with low immunity who have chronic conditions, and healthcare workers are all at risk for influenza infection. As a result, the Europe need for vaccines has skyrocketed. Such factors are likely to propel the worldwide plant-based vaccines market forward during the forecast period.    

Key Market Segments

Europe plant-based vaccines market is segmented into vaccine type, source, application, and country. Based on vaccine type, the Europe plant-based vaccines market is segmented into bacterial vaccines, viral vaccines, parasite vaccines, plant-derived virus-like particles, and others. The bacterial vaccines segment held the largest share of the market in 2021. Based on source, the Europe plant-based vaccines market is segmented into tobacco plant, maize, potato, and others. The tobacco plant segment held the largest share of the market in 2021. Based on application, the Europe plant-based vaccines market is segmented into influenza, zika virus, Ebola virus, poultry disease, COVID-19, and others. The influenza segment held the largest share of the market in 2021. Based on country, the Europe plant-based vaccines market is segmented into France, Germany, Italy, Spain, the UK, and rest of Europe. Germany held the largest market share in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the plant-based vaccines market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are British American Tobacco p.l.c.; Creative Biolabs, Inc.; Leaf Expression Systems Ltd.; LenioBio; Lumen Bioscience, Inc.; and ZYUS Life Sciences Inc.        

Reasons to buy report

• To understand the Europe plant-based vaccines market landscape and identify market segments that are most likely to guarantee a strong return.
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe plant-based vaccines market.
• Efficiently plan M&A and partnership deals in Europe plant-based vaccines market by identifying market segments with the most promising probable sales.
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe plant-based vaccines market.
• Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

Europe Plant-based Vaccines Market Segmentation
Europe Plant-based Vaccines Market - By Vaccine Type

• Bacterial Vaccines
• Viral Vaccines
• Parasite Vaccines
• Plant-Derived Virus-Like Particles
• Others

Europe Plant-based Vaccines Market - By Source

• Tobacco Plant
• Maize
• Potato
• Others

Europe Plant-based Vaccines Market - By Application

• Influenza
• Zika Virus
• Ebola Virus
• COVID-19
• Poultry Disease
• Others

Europe Plant-based Vaccines Market - By Country

• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe 

Europe Plant-based Vaccines Market - Company Profiles

• British American Tobacco p.l.c.
• Creative Biolabs, Inc.     
• Leaf Expression Systems Ltd.
• LenioBio
• Lumen Bioscience, Inc.
• ZYUS Life Sciences Inc.

Europe Plant-based Vaccines Market Strategic Insights

Europe Plant-based Vaccines Market Report Highlights

Europe Plant-based Vaccines Market Country and Regional Insights